Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full...(predictedinclude without limitation comm...),Health

Date:7/31/2008

predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the full-year period ended December 31, 2007, most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

[Financial tables follow]

GENOPTIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenues $27,825 $13,948 $50,123 $24,599

Cost of revenues 11,206 5,393 20,381 10,030

Gross profit 16,619 8,555 29,742 14,569

Operating expenses:

Sales and marketing 5,170 2,421 9,431 4,742

General and administrative 5,918 2,131 10,306 4,265

Research and development 354 142 671 320

Total operating expenses 11,442 4,694 20,408 9,327

Income from operations 5,177
'/>"/>

SOURCE Genoptix, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Genoptix Reports Strong Financial Results for First Quarter 2008
2. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
3. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
4. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
5. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
6. Genoptix Announces Pricing of Secondary Public Offering
7. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
8. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
9. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
10. Genoptix, Inc. Announces Pricing for Initial Public Offering
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update